( April 28, 2026, 16:59 GMT | Official Statement) -- MLex Summary: Eli Lilly and Novo Nordisk told a US federal judge they didn't enter into exclusive agreements with telehealth platforms to block those platforms from selling Strive’s competing compounded GLP-1 drugs, moving to dismiss antitrust claims filed by Strive Specialties. They said the actual agreements, incorporated by reference into Strive’s complaint, only require telehealth platforms to comply with “all applicable laws and professional standards.” So, if the agreements impact Strive at all, it could only be because Strive illegally mass-produces unapproved knockoffs of medicines approved by the Food and Drug Administration, which it refuses to say outright.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.